title: Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.
abstract: Cerebral involvement of systemic mastocytosis and intracranial sarcoma of myelogenic origin are well known entities. An 8-year-old girl with an isolated cerebral mast cell tumor is presented. Specific histopathologic stains were used to confirm the diagnosis detecting immunophenotype and proliferative activity. Treatment with irradiation, intrathecal cytarabine, and interferon-alpha2b did not induce regression whereas polychemotherapy did. Systemic combination chemotherapy led to marked transient tumor regression in this proliferating mast cell sarcoma in an unusual intracranial location.
authors.affiliation: Department of Pediatrics, Technical University Dresden, Germany. gunk4@yahoo.de
authors.forename: P P
authors.initials: PP
authors.lastname: Guenther
authors.forename: A
authors.initials: A
authors.lastname: Huebner
authors.forename: S B
authors.initials: SB
authors.lastname: Sobottka
authors.forename: V
authors.initials: V
authors.lastname: Neumeister
authors.forename: G
authors.initials: G
authors.lastname: Weissbach
authors.forename: H
authors.initials: H
authors.lastname: Todt
authors.forename: R
authors.initials: R
authors.lastname: Parwaresch
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D003630:Daunorubicin / Q000008:administration & dosage; D018450:Disease Progression; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006261:Headache / Q000209:etiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007278:Injections, Spinal; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D012515:Mast-Cell Sarcoma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D009325:Nausea / Q000209:etiology; D009364:Neoplasm Recurrence, Local; D010166:Palliative Care; D010211:Papilledema / Q000209:etiology; D010296:Parietal Lobe / Q000473:pathology* / Q000601:surgery; D011239:Prednisolone / Q000008:administration & dosage; D011867:Radioisotope Teletherapy; D011994:Recombinant Proteins; D012074:Remission Induction; D015173:Supratentorial Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D013702:Temporal Lobe / Q000473:pathology* / Q000601:surgery; D017211:Treatment Failure; D014839:Vomiting / Q000209:etiology
chemical_list: D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003561:Cytarabine; D005047:Etoposide; D011239:Prednisolone; D003630:Daunorubicin